Docket: A-65-16
Citation: 2017 FCA 51
CORAM:
|
GAUTHIER J.A.
DE MONTIGNY J.A.
GLEASON J.A.
|
BETWEEN:
|
TEVA CANADA
LIMITED
|
Appellant
|
and
|
LEO PHARMA INC.
AND LEO PHARMA A/S
|
Respondents
|
and
|
THE
MINISTER OF HEALTH
|
Respondent
|
Heard
at Montréal, Quebec, on February 2,
2017.
Judgment delivered at Ottawa, Ontario,
on March 14, 2017.
REASONS FOR JUDGMENT BY:
|
GAUTHIER J.A.
|
CONCURRED IN BY:
|
DE MONTIGNY J.A.
GLEASON J.A.
|
Docket: A-65-16
Citation: 2017 FCA 51
CORAM:
|
GAUTHIER J.A.
DE MONTIGNY J.A.
GLEASON J.A.
|
BETWEEN:
|
TEVA CANADA
LIMITED
|
Appellant
|
and
|
LEO PHARMA INC.
AND LEO PHARMA A/S
|
Respondents
|
and
|
THE
MINISTER OF HEALTH
|
Respondent
|
REASONS
FOR JUDGMENT
GAUTHIER J.A.
[1]
In the present appeal, the appellant, Teva Canada
Limited, seeks to set aside the decision of the Federal Court (2016 FC 107)
granting the respondent, Leo Pharma Inc., costs in the amount of $419,729.92 in
respect of its successful application under the Patented Medicines (Notice
of Compliance) Regulations, SOR/93-133. In its detailed reasons, the
Federal Court disallowed a substantial portion of the amount claimed by Leo
Pharma but it rejected the specific arguments raised before us by Teva in
respect of additional deductions.
[2]
Teva makes two alternative submissions. First,
it requests that in the event its appeal on the merits of the Federal Court’s
prohibition application is successful the costs award should be set aside.
Second, it submits in the alternative that even if its appeal on the merits of the
decision on the prohibition application is dismissed, the costs award should be
reduced to deduct some or all of the amounts awarded for certain fees paid to
Leo Pharma’s experts (Dr. Goldberg, Dr. Shear, and Dr. Blatter).
[3]
As a discretionary decision, the Federal Court’s
decision on costs is reviewable under the usual appellate standard of review
set out in Housen v. Nikolaisen, [2002] 2 S.C.R. 235, 2002 SCC 33:
factual determinations and matters of mixed fact and law which do not contain
an extricable legal issue may be set aside only if the Federal Court made a
palpable and overriding error whereas legal errors are subject to review for
correctness: Hospira Healthcare Corporation v. Kennedy Institute of
Rheumatology, 2016 FCA 215 at paragraphs 74-79.
[4]
The first of Teva’s submission must be dismissed
as its appeal on the merits of the Federal Court’s prohibition application was
unsuccessful on the merits (2017 FCA 50). I would also dismiss its alternative
submission.
[5]
Indeed, each of the impugned portions of the
Federal Court’s costs award involves a matter of fact or mixed fact and law
from which no pure issue of law can be extricated. I do not see any error, much
less a palpable and overriding one, having been made by the Federal Court in
respect of any of the said portions of its costs award.
[6]
I would therefore dismiss this appeal with costs
that I would fix in the all-inclusive amount of $500.00.
“Johanne Gauthier”
“I agree
|
Yves de Montigny J.A.”
|
“I agree
|
Mary J.L. Gleason J.A.”
|
FEDERAL
COURT OF APPEAL
NAMES
OF COUNSEL AND SOLICITORS OF RECORD
APPEAL FROM AN ORDER OF THE
HONOURABLE JUSTICE LOCKE DATED JANUARY 29, 2016, DOCKET NO. T-1791-13 (2016 FC
107)
STYLE OF CAUSE:
|
TEVA CANADA LIMITED v. LEO PHARMA
INC. AND LEO PHARMA A/S and THE MINISTER OF HEALTH
|
|
PLACE OF HEARING:
|
Montréal, Quebec
|
DATE OF HEARING:
|
February 2, 2017
|
REASONS FOR JUDGMENT BY:
|
GAUTHIER J.A.
|
CONCURRED IN BY:
|
DE MONTIGNY J.A.
GLEASON J.A.
|
DATED:
|
March 14, 2017
|
|
|
|
|
APPEARANCES:
Jonathan Stainsby
|
For The Appellant
|
Julie Desrosiers
Marie Lafleur
Christian Leblanc
Alain Leclerc
Kang Lee
|
For The
Respondent
LEO PHARMA INC. AND LEO PHARMA A/S
|
Maguy Hachem
|
For The
Respondent
THE MINISTER OF HEALTH
|
SOLICITORS OF RECORD:
Aitken Klee LLP
Toronto, ON
|
For The
Appellant
|
Fasken Martineau DuMoulin LLP
Montreal, Quebec
|
For The
Respondent
LEO PHARMA INC. AND LEO PHARMA A/S
|
William F. Pentney
Deputy Attorney General of Canada
|
For The
Respondent
THE MINISTER OF HEALTH
|